December 8, 2025BloodOpen Access

Efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis finds blinatumomab leads to high remission rates in infant ALL, suggesting its role in improving treatment.

Evaluate the efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia (IALL).
Retrospective analysis of 11 IALL patients treated with blinatumomab at a single center.
Patients were under 12 months and had not received prior IALL treatment.
Risk stratification followed CCLG-2018-ALL protocol, with blinatumomab administered during various treatment phases.
All patients achieved complete remission after 15 days of induction therapy.
Some patients achieved minimal residual disease negativity after blinatumomab treatment.
Early administration of blinatumomab showed favorable outcomes for remission and manageable adverse effects.

Lin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds blinatumomab leads to high remission rates in infant ALL, suggesting its role in improving treatment.

Evaluate the efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia (IALL).
Retrospective analysis of 11 IALL patients treated with blinatumomab at a single center.
Patients were under 12 months and had not received prior IALL treatment.
Risk stratification followed CCLG-2018-ALL protocol, with blinatumomab administered during various treatment phases.
All patients achieved complete remission after 15 days of induction therapy.
Some patients achieved minimal residual disease negativity after blinatumomab treatment.
Early administration of blinatumomab showed favorable outcomes for remission and manageable adverse effects.

Lin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark